Introducing the “In Favour Of” filter in Case Laws.
- ⚖️ Instantly identify judgments decided in favour of the Assessee, Revenue, or Appellant
- 🔍 Narrow down results with higher precision
Try it now in Case Laws →
TaxTMI Login
🚀 New Feature Launched ✕
Just a moment...
Introducing the “In Favour Of” filter in Case Laws.
Try it now in Case Laws →
Press 'Enter' to add multiple search terms. Rules for Better Search
of 
of 
No Folders have been created
Are you sure you want to delete "My most important" ?
NOTE:
of of 
All Circulars
of of All Circulars
Note
Bookmark
Share
Don't have an account? Register Here
of <h1>India De-licenses Vitamin B1, B2, Tetracycline, Oxytetracycline, Folic Acid Manufacturing; Eases Industrial Licensing Rules.</h1> The Government of India has decided to de-license the manufacture of five bulk drugs: Vitamin B1, Vitamin B2, Tetracycline, Oxytetracycline, and Folic Acid, previously reserved for the Public Sector under the Drug Policy. This move is part of ongoing industrial reforms, removing the need for industrial licensing under the Industries (Development and Regulation) Act. However, drugs produced using recombinant DNA technology and certain other specified formulations will remain under compulsory licensing. Entrepreneurs interested in manufacturing these de-licensed drugs must file an Industrial Entrepreneurs' Memorandum, except those with existing Letters of Intent, who need only file Part 'B' of the IEM.
TaxTMI 
TaxTMI 
